Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland.
Curr Opin Clin Nutr Metab Care. 2011 Sep;14(5):497-503. doi: 10.1097/MCO.0b013e328348c033.
To review interactions between the microbiota and the host in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), emphasizing areas of commonality and divergence.
Several lines of evidence support a role for the microbiota in the pathogenesis of IBS and IBD. Some implicate the microbiota in a general sense and relate to variations in the composition of the microbiota between IBS, IBD and controls; others relate to the ability of events and interventions that disrupt/modify the microbiota to predispose to the development of IBS and IBD and, others still refer to reports of the ability of antibiotics, prebiotics or probiotics, in selected circumstances, to beneficially alter their clinical course. Enthusiasm for a role for a specific organism in precipitating disease has been largely (and contentiously) linked to IBD. Many issues remain unresolved and must wait for the application of modern microbiological techniques to well characterized populations and well matched controls.
It makes sense, given the size and complexity of the microbiota and its role in homeostasis, that the microbiota and its interactions with the host would play a role in the pathogenesis of IBS and IBD; sorting out the details has proven challenging but does offer new therapeutic avenues for both disorders.
综述肠易激综合征(IBS)和炎症性肠病(IBD)中微生物组与宿主的相互作用,强调共性和分歧领域。
有几项证据支持微生物组在 IBS 和 IBD 发病机制中的作用。一些证据从总体上暗示了微生物组的作用,并与 IBS、IBD 和对照组之间微生物组组成的变化有关;其他证据则与能够破坏/改变微生物组的事件和干预措施易导致 IBS 和 IBD 发展有关;还有一些证据涉及在特定情况下抗生素、益生元和益生菌能够有益地改变其临床病程的报道。在引发疾病方面,对特定生物体的作用的热情在很大程度上(且颇具争议性)与 IBD 有关。许多问题仍未解决,必须等待现代微生物学技术应用于具有明确特征的人群和匹配良好的对照组。
鉴于微生物组的大小和复杂性及其在体内平衡中的作用,微生物组及其与宿主的相互作用很可能在 IBS 和 IBD 的发病机制中发挥作用;理清这些细节具有挑战性,但确实为这两种疾病提供了新的治疗途径。